The combination of DNMT inhibitor and PARP inhibitor in several preclinical cancer models also observed a synergistic effect of inducing ICD, further indicating the importance of genetic and epigenetic modulation in cancer therapy.49 This evidence concerns the gene DNMT1 and cancer.